Nishan Rajakumaraswamy
Company: Gilead Sciences
Job title: Director Clinical Research Oncology/ Hematology
Seminars:
Live Q&A – Ask the Speakers Your Burning Questions 2:30 pm
day: Day One
A Gilead Case Study: Bringing the First PI3K Delta Inhibitor to the Market 1:30 pm
Gilead’s idelalisib (Zydelig) was the first PI3K delta inhibitor to gain approval from the FDA and EMA in selected hematological malignancies in 2014. We revisit the key clinical trial data leading to approval, use in the clinic along with lessons learnt, how the safety profile can be potentially optimized and some possible future directions.Read more
day: Day One